FUZIM-CV combines Cefuroxime Axetil, a second-generation cephalosporin antibiotic, with
Potassium Clavulanate, a β-lactamase inhibitor. This synergistic combination provides potent
bactericidal activity and overcomes resistance caused by β-lactamase-producing organisms.

Key Benefits:
● Broad-spectrum coverage against gram-positive and gram-negative bacteria
● Effective against β-lactamase-producing resistant bacterial strains
● Ideal for moderate to severe bacterial infections
● Twice-daily dosing ensures effective plasma concentration and patient compliance
● Well-tolerated with a favorable safety profile

Indications:
● Acute bacterial sinusitis
● Community-acquired pneumonia
● Chronic and acute bronchitis
● Complicated urinary tract infections
● Skin and soft tissue infections
● ENT infections (e.g., tonsillitis, otitis media)